Internal tandem duplications of the FMS-related tyrosine kinase 3 (FLT3-ITD) have consistently been identified as an unfavorable molecular marker in both relapsed and refractory AML [7, 10]. The gene discussed is FLT3; the disease is acute myeloid leukemia.